Think You Know the Latest ASH Leukemia & Lymphoma Research?
Do you remember the leukemia and lymphoma research presented at ASH? Test your knowledge now and see how you rank!
Read MoreFeb 22, 2024
Do you remember the leukemia and lymphoma research presented at ASH? Test your knowledge now and see how you rank!
Read MoreFeb 8, 2024
A curated eBook featuring 65th ASH Annual Meeting leukemia and lymphoma-focused studies, findings, and expert opinions.
Read MoreJan 26, 2024
Research from ASH 2023 showed standard treatment options lack efficacy for patients who are positive for the TP53 mutation with AML.
Read MoreJan 8, 2024
Patients reporting increased fatigue have a higher hazard of death compared with those who did not after adjusting for covariates.
Read MoreDec 22, 2023
Treatment that includes acalabrutinib can improve progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia.
Read MoreDec 18, 2023
A sandwich treatment model that includes acalabrutinib and rituximab in combination with R-DHAOx chemotherapy shows encouraging results in phase 2 trial.
Read MoreDec 5, 2023
The following is a summary of “Benefit of Allogeneic Transplant in 1st Complete Remission in...
Read MoreDec 5, 2023
The following is a summary of “Autologous Transplant (auto-HCT) Is Associated with Improved...
Read MoreDec 5, 2023
The following is a summary of “Addition of Acalabrutinib to Lenalidomide and Rituximab...
Read MoreDec 4, 2023
With over 275 exhibitors, the 65th ASH Annual Meeting exhibit hall is not to be missed!
Read MoreDec 4, 2023
Sign up today for the virtual 2023 ASH Foundation Run/Walk!
Read MoreDec 4, 2023
Make the most of your attendance at the 65th ASH annual meeting by utilizing these helpful resources to plan your schedule and stay informed!
Read More